Brisbane, California –(Business Wire)–Johnson & Johnson (NYSE: JNJ) (the Company) today opened the San Francisco Bay Campus, a state-of-the-art research and development (R&D) facility in the Bay Area, one of the most mature global facilities in the world A hub for innovation and entrepreneurship. The nearly 200,000-square-foot facility will house up to 400 employees, more than double the size of Johnson & Johnson’s R&D in the Bay Area. The campus connects key technological capabilities by co-locating Janssen R&D, J&J Innovation and J&J Technology. It will further integrate the company into the Bay Area innovation ecosystem to strengthen and increase collaboration with innovators to accelerate growth.
“Johnson & Johnson’s expansion in the Bay Area is a testament to our commitment to combining technology to deliver transformative healthcare solutions,” said Joaquin Duato, CEO of Johnson & Johnson. “On this campus, we are full of talent. Our team will use their extensive experience and expertise to tackle society’s greatest health challenges and create a better future for patients. ”
R&D at the new site focuses on Janssen’s therapeutic areas and key functions, including emerging science and technologies in gene and RNA therapeutics, new therapies and approaches in retinal and infectious diseases, and advanced data science including artificial intelligence and machine learning. Concentrating expertise at this location will allow the company’s world-class discovery engine and industry-leading pipeline to expand.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform the way we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, Our goal is to accelerate the growth of our best-in-class product portfolio and deliver better health outcomes for people around the world,” said James Merson, Ph.D., San Francisco Bay Site Leader, Infectious Disease Campus and Global Therapeutic Area Leader, Janssen Research & Development, LLC .
Since 2014, the Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystems. The San Francisco Bay Campus, along with the company’s JLABS @ South San Francisco, will continue to enable the company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives around the world. Additionally, given the convergence of healthcare and technology in the region, the company will increase its focus on Johnson & Johnson’s technology organization to enhance its ability to create innovative digital solutions to advance human health.
Building on Johnson & Johnson’s long-standing commitment to using its expertise and resources to reduce the environmental footprint of its operations, the Bay Area Hub is designed as a high-performance green campus that reinforces the company’s commitment to creating health as a responsible steward. , a more sustainable future. The goal is for the new site to be certified by Energy and Environmental Design (LEED), the world’s most widely used green building rating system.
About Johnson & Johnson
At Johnson & Johnson, we believe that good health is the foundation of vibrant lives, thriving communities and moving forward. That’s why for more than 135 years, we’ve been working to keep people healthy at every age and at every stage of life. Today, as the largest and broadest healthcare company in the world, we are committed to maximizing our reach and scale. We work to improve accessibility and affordability, create healthier communities, and put healthy minds, bodies and environments within the reach of everyone, everywhere. We are merging our hearts, science and ingenuity to profoundly change the trajectory of human health. Visit www.jnj.com for more information. Follow us at @JNJNews.
About Johnson & Johnson’s Janssen Pharmaceutical Company
At Janssen, we are creating a future where disease is a thing of the past. We are a pharmaceutical company owned by Johnson & Johnson, and we work tirelessly to fight disease with science, improve access with ingenuity, heal despair with heart, and make this future a reality for patients everywhere. We focus on the areas of medicine where we can make the most of our difference: Cardiovascular, Metabolism and Retinal; Immunology; Infectious Diseases and Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Visit www.janssen.com for more information. Follow us at @JanssenGlobal. Janssen Research and Development, LLC is part of the Janssen Pharmaceutical Company of Johnson & Johnson.
About Johnson & Johnson Innovation
Johnson & Johnson Innovations LLC works in pharmaceuticals, medical devices and consumer health to accelerate early-stage transformational solutions by catalyzing the best ideas around the world. We do this by leveraging our deep scientific capabilities as well as a wide range of tools, including custom deal structuring, company creation, incubation and start-up services, capital investments and other innovative business models designed to cater to entrepreneurs, scientists and emerging companies. Our goal is to help life sciences and health technology innovation thrive through collaboration and partnership with global ecosystems that collectively change the trajectory of human health. Meet our passionate team of tech experts at www.jnjinnovation.com and learn how to work with us.
About Johnson & Johnson
Johnson & Johnson solves big problems in healthcare through technology and digital innovation. Like a doctor with a scalpel, we use data science, algorithms, artificial intelligence, robotics and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from anywhere, our digital tools infuse our products with novelty, flexibility and ease of use. Guided by our creed, we unleash the power of technology to drive greater access, equity, and sustainability, and shape the future of healthcare in a way that only we can.
Caution Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which include: future operating and financial performance, product development, market position and business strategy. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or if known or unknown risks or uncertainties arise, actual results may differ materially from Janssen R&D LLC’s expectations and projections. Risks and uncertainties include, but are not limited to: economic factors, such as interest rates and currency exchange rate fluctuations; competition, including technological advancements, new products and patents acquired by competitors; challenges inherent in the development of new products, including uncertainty about clinical success and obtaining regulatory approvals; uncertainty about the commercial success of new and existing products; challenges to patents; impact of patent expirations; company’s ability to successfully execute strategic plans; impact of business mergers and divestitures; manufacturing in-house or within supply chains Difficulties or delays; Product efficacy or safety issues leading to product recalls or regulatory actions; Material adverse litigation or government action, including in relation to product liability claims; Changes in applicable laws and regulations, including tax laws and global healthcare reform; Trends in healthcare cost control Changes in the behavior and consumption patterns of buyers of medical products and services; Financial instability and sovereign risks to the international economic and legal system; Increased scrutiny of the healthcare industry by government agencies; the necessary conditions for the separation of the business; the company’s ability to successfully separate the company’s consumer health business and realize the expected benefits of the separation; the ability of the new consumer health company to succeed as an independent public company; and the risks associated with the impact of the COVID-19 global pandemic, Examples include the scope and duration of the outbreak, government actions and restrictive measures in response, significant delays and cancellations of medical procedures, supply chain disruptions, and other impacts to business, or the company’s execution of business continuity due to the COVID-19 pandemic capacity for sexual planning. For a further list and description of these risks, uncertainties and other factors, please see Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including the heading “Cautionary Note Regarding Forward-Looking Statements” section” and “Item 1A. Risk Factors”, and Johnson & Johnson’s subsequent quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, or upon request by Johnson & Johnson Any forward-looking statements in this press release speak only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.